KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Minority Interest: 2019-2025

Historic Minority Interest for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $3.2 billion.

  • Royalty Pharma's Minority Interest fell 5.37% to $3.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 billion, marking a year-over-year decrease of 5.37%. This contributed to the annual value of $3.4 billion for FY2024, which is 4.55% down from last year.
  • Royalty Pharma's Minority Interest amounted to $3.2 billion in Q3 2025, which was up 1.63% from $3.2 billion recorded in Q2 2025.
  • Royalty Pharma's 5-year Minority Interest high stood at $5.0 billion for Q1 2021, and its period low was $3.1 billion during Q1 2025.
  • Over the past 3 years, Royalty Pharma's median Minority Interest value was $3.4 billion (recorded in 2024), while the average stood at $3.4 billion.
  • Data for Royalty Pharma's Minority Interest shows a maximum YoY dropped of 19.38% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Royalty Pharma's Minority Interest stood at $4.5 billion in 2021, then fell by 12.85% to $3.9 billion in 2022, then decreased by 8.71% to $3.6 billion in 2023, then declined by 4.55% to $3.4 billion in 2024, then fell by 5.37% to $3.2 billion in 2025.
  • Its last three reported values are $3.2 billion in Q3 2025, $3.2 billion for Q2 2025, and $3.1 billion during Q1 2025.